top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau to Participate in Five September Investor Conferences
JERUSALEM, August 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 27
Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical PromiseAn interview with Prof. Aron Popovtzer
Combining Alpha DaRT® and Immunotherapy: Early Results and Clinical Promise An interview with Prof. Aron Popovtzer, Director of Sharett...
Jul 10
Alpha Tau to Present at Jefferies Global Healthcare Conference
JERUSALEM, May 28, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 28
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium...
May 20
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ), ("Alpha Tau" or the "Company"), the developer of the...
May 13
bottom of page